HDL的临床试验PPT课件.ppt

《HDL的临床试验PPT课件.ppt》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、HDLandCoronaryHeartDiseaseAngiographicandClinicalEventTrialsAngiographicTrialsofCombinationTherapyCholesterolLoweringAtherosclerosisStudy(CLAS)1Dietandniacin+colestipol(vsdietandplacebo)188men(aged40–59y),post-CABGNonsmokersorformersmokers,nondiabetic,non

2、hypertensiveTotal-Catentry:185–350mg/dL;drugresponsiveFamilialAtherosclerosisTreatmentStudy(FATS)2Lovastatin+colestipol,niacin+colestipol,orconventionaltherapy146men(aged62y)withCADandfamilyhistoryofCADApoB125mg/dLAveragestenosis:34%1.BlackenhornDHetal.J

3、AMA.1987;257:3233–32402.BrownGetal.NEnglJMed.1990;323:1289–1298AngiographicTrialsofCombinationTherapyEffectsonLipids%changeTrialLDL-CHDL-CTGCLASPlacebo(2y)15*25*Niacin+colestipol(2y)143*37*22*Niacin+colestipol(4y)240††37††18§FATS(2.5y)3Convention

4、al7**6**15Niacin+colestipol32*41*29*Lovastatin+colestipol45*16†9Versusbaseline:*P<0.001;†P<0.01;**P<0.05;Versusplacebo:††P<0.001;§P<0.031.BlankenhornDHetal.JAMA1987;257:3233–32402.Cashin-HemphillLetal.JAMA1990;264:3013–30173.BrownBGetal.NEnglJMed1

5、990;323:1289–1298Cholesterol-LoweringAtherosclerosisStudy(CLAS)UnivariateApoPredictorsofCoronaryProgressionMean(mg/dL)PredictorProgressorNonprogressorPvaluePlacebo(n=82:49progressors,33nonprogressors)ApoB1281160.03ApoC-III(total)12.410.30.03ApoC-III(HS)*5.

6、94.90.03Drug(n=80:31progressors,49nonprogressors)ApoC-III(HS)*6.47.50.05*HS=heparinsupernate(apoC-IIIinHDL)BlankenhornDHetal.Circulation1990;81:470–476FamilialAtherosclerosisTreatmentStudy(FATS)UnivariatePredictorsofChangeinProximalStenosisPredictorrPval

7、ueApoB0.38<0.0001LDL-C0.27<0.01HDL-C-0.33<0.001ApoA-I-0.28NotreportedBrownGetal.NEnglJMed1990;323:1289–1298AngiographicTrialsofFibrateTherapyBezafibrateCoronaryAtherosclerosisInterventionTrial(BECAIT)1Bezafibratevsplacebo92malesurvivorsofMI,aged<45yattimeo

8、feventCoronaryangiographyatbaselineandafter2and5yLopidCoronaryAngiographyTrial(LOCAT)2Gemfibrozilvsplacebo395men,post-CABGCoronaryangiographyatbaselineandafter32mos1.EricssonCGetal.Lancet1996;347:849–8532.Fri